Merimepodib [198821-22-6]

Biological Activity

Merimepodib, also known as VX-497, is an orally bioavailable IMPDH inhibitor with broad spectrum antiviral activities. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. 

In vivo, oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED(50) value of approximately 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation.

Chemical Information

Molecular Weight	452.46
Formula	C23H24N4O6
CAS Number	198821-22-6
Solubility (25°C)	DMSO ≥ 27 mg/mL
Storage	Powder          -20°C   3 years ;  4°C   2 years In solvent       -80°C   6 months ;  -20°C   1 month

References

[1] C J Decker, et al. Dvrgs Exp Clin Res. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice

[2] J Jain, et al. J Pharm Sci. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent

[3] W Markland, et al. Antimicrob Agents Chemother. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon